Skip to content

The effect of GLP-1 analogue on cognitive decline in diabetes: A resting-state fMRI study on type 2 diabetes

The effect of GLP-1 analogue on cognitive decline in diabetes: A resting-state fMRI study on type 2 diabetes

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-13003095
Enrollment
Unknown
Registered
2013-02-17
Start date
2013-03-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

intervention patients:GLP-1 analogue
diabetes without cognitive decline:oral medicine
diabetes with cognitive decline:oral medicine
normal control:none

Sponsors

affiliated ZhongDa Hospital of Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All patients met the diagnosis of T2DM according to the World Health Organization 1999 criteria (Alberti and Zimmet, 1998); 2. MMSE=8 years; 6. right handed; 7. No electronic, metal devices implanted (cardiac pacemaker, defibrillator, stent, orthopaedics steel, etc); 8. Good visual and hearing function.

Exclusion criteria

Exclusion criteria: Participants were excluded from the study if they had a past history of known stroke, alcoholism, head injury, Parkinson's disease, epilepsy, major depression (excluded by self-rating depression scale) or other neurological or psychiatric illness (excluded by clinical assessment and case history), major medical illness (e.g., cancer, anaemia and thyroid dysfunction) and severe visual or hearing loss.

Design outcomes

Primary

MeasureTime frame
glucose;blood lipid;height;weight;MRI information;C-peptid;

Countries

China

Contacts

Public ContactShaohua Wang
gyjwsh@yahoo.cn+86 13701581801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026